Search

Omeros Corp

Ouvert

SecteurSoins de santé

17.18 -0.81

Résumé

Variation du prix de l'action

24h

Actuel

Min

16.17

Max

17.88

Chiffres clés

By Trading Economics

Revenu

-35M

51M

Ventes

9.9M

9.9M

P/E

Moyenne du Secteur

11.641

57.002

BPA

0.57

Marge bénéficiaire

518.033

Employés

175

EBITDA

86M

57M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+140.7% upside

Dividendes

By Acuity

Prochains Résultats

12 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-53M

983M

Ouverture précédente

17.99

Clôture précédente

17.18

Sentiment de l'Actualité

By Acuity

57%

43%

286 / 340 Classement par Healthcare

Omeros Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 août 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, following notable volatility without any specific company news to explain the decline.

12 août 2026, 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

11 août 2026, 23:41 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

10 août 2026, 23:51 UTC

Omeros Corp shares are lower in after-market hours, influenced by a recent labor report indicating job losses and reduced Fed rate hike expectations.

8 août 2026, 00:02 UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7 août 2026, 23:31 UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6 août 2026, 23:01 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

5 août 2026, 23:51 UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

4 août 2026, 23:02 UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3 août 2026, 23:11 UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

1 août 2026, 00:01 UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

31 juil. 2026, 23:41 UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

30 juil. 2026, 16:06 UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

29 juil. 2026, 18:58 UTC

Social Media

Omeros Corp is trading higher today, driven by positive social media sentiment despite broader weakness in the XBI sector. Market volume remains unusually high.

28 juil. 2026, 19:16 UTC

Social Media

Omeros Corp shares are lower today after earlier declines, amid social media discussions highlighting reduced competition following AstraZeneca's failed trial related to HSCT-TMA.

27 juil. 2026, 21:01 UTC

Omeros Corp shares are higher in after-market hours, following a broader market trend amid easing geopolitical tensions and declining oil prices.

24 juil. 2026, 19:26 UTC

Omeros Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the movement.

22 juil. 2026, 18:46 UTC

Omeros Corp shares are higher today, continuing an upward trend since Tuesday. Broader market dynamics are influenced by rising crude oil prices amid geopolitical tensions.

21 juil. 2026, 23:06 UTC

Omeros Corp. shares traded roughly flat in after-market hours. The stock remains below its 20-day moving average, marking three consecutive lower daily closes.

20 juil. 2026, 19:26 UTC

Omeros Corp shares are higher today, despite an earlier pullback. The stock has stabilized since Friday's close within its one-month trading range.

Comparaison

Variation de prix

Omeros Corp prévision

Objectif de Prix

By TipRanks

140.7% hausse

Prévisions sur 12 Mois

Moyen 33 USD  140.7%

Haut 33 USD

Bas 33 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

286 / 340Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat